[Vandetanib (medullary thyroid carcinoma in children and adolescents from the age of 5) – Benefit assessment according to § 35a Social Code Book V]


Original post, click here

Record Status

This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Vandetanib (Schilddrüsenkarzinom): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A17-01. [Vandetanib (medullary thyroid carcinoma in children and adolescents from the age of 5) – Benefit assessment according to § 35a Social Code Book V] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 506. 2017

Indexing Status

Subject indexing assigned by CRD

MeSH

Piperidines; Quinazolines; Thyroid Neoplasms

English summary

There is no English language summary available.

Address for correspondence

IQWiG, Im Mediapark 8, DE-50670 Cologne, GERMANY, Tel: +49 (0) 221 – 35685 – 0, Fax: +49 (0) 221 – 35685 – 1 Email: berichte@iqwig.de